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Consider melatonin 
for migraine prevention 
This affordable, over-the-counter hormone is as effective 
as amitriptyline, causes fewer adverse effects, and may 
have a surprising added benefit. 
PRACTICE CHANGER
Recommend nightly melatonin 3 mg to your 
patients with chronic migraines, as it appears 
to be as effective as amitriptyline in reducing 
headaches and causes fewer adverse effects. 
STRENGTH OF RECOMMENDATION
B: Based on a single, good quality random-
ized controlled trial.
Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Randomised clini-
cal trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo 
for migraine prevention. J Neurol Neurosurg Psychiatry. 2016;87:1127-
1132.1
ILLUSTRATIVE CASE
A 32-year-old woman comes to your office 
for help with her recurrent migraines, which 
she’s had since her early 20s. She is otherwise 
healthy and active. She is frustrated over the 
frequency of her migraines and the debilita-
tion they cause. She has tried prophylactic 
medications in the past, but stopped taking 
them because of the adverse effects. What do 
you recommend for treatment?
Daily preventive medication can be helpful for chronic migraine suffer-ers whose headaches have a signifi-
cant impact on their lives and who have a goal 
of reducing headache frequency or severity, 
disability, and/or avoiding acute headache 
medication escalation.2 An estimated 38% of 
patients with migraines are appropriate candi-
dates for prophylactic therapy, but only 3% to 
13% are taking preventive medications.3 
Evidence-based guidelines from the 
American Academy of Neurology and the 
American Headache Society state that 
antiepileptic drugs (divalproex sodium, 
sodium valproate, topiramate) and many 
beta-blockers (metoprolol, propranolol, 
timolol) are effective and should be recom-
mended for migraine prevention (level A 
recommendation; based on ≥2 class I tri-
als).2 Medications such as antidepressants 
(amitriptyline, venlafaxine) and other beta-
blockers (atenolol, nadolol) are probably 
effective and can be considered (level B rec-
ommendation; based on one class I trial or 
2 class II trials).2 However, adverse effects, 
such as somnolence, are listed as frequent 
with amitriptyline and occasional to fre-
quent with topiramate.4
Researchers have investigated melato-
nin before. But a 2010 double-blind, cross-
over, randomized controlled trial (RCT) of 
46 patients with 2 to 7 migraine attacks per 
month found no significant difference in 
reduction of headache frequency with 
extended-release melatonin 2 mg taken one 
hour before bed compared to placebo over an 
8-week period.5
STUDY SUMMARY
Melatonin tops amitriptyline in >50% 
improvement in headache frequency
This RCT conducted in Brazil compared 
the effectiveness of melatonin to amitripty-
line and placebo for migraine prevention in 
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196 adults (ages 18-65 years) with chronic 
migraines.1 Eligible patients had a history 
of at least 3 migraine attacks or 4 migraine 
headache days per month. Patients were 
randomized to take identically-appearing 
melatonin 3 mg, amitriptyline 25 mg, or pla-
cebo nightly. The investigators appear to have 
concealed allocation adequately, and used 
double-blinding. 
The primary outcome was the number of 
headache days per month, comparing base-
line with the 4 weeks of treatment. Secondary 
endpoints included reduction in migraine 
intensity, duration, number of analgesics 
used, and percentage of patients with more 
than 50% reduction in migraine headache 
days. 
Compared to placebo, headache days 
per month were reduced in both the melato-
nin group (6.2 days vs 4.6 days, respectively; 
mean difference [MD], -1.6; 95% confidence 
interval [CI], -2.4 to -0.9) and the amitripty-
line group (6.2 days vs 5 days, respectively; 
MD, -1.1; 95% CI, -1.5 to -0.7) at 12 weeks, 
based on intention-to-treat analysis. Mean 
headache intensity (0-10 pain scale) was also 
lower at 12 weeks in the melatonin group 
(4.8 vs 3.6; MD, -1.2; 95% CI, -1.6 to -0.8) and 
in the amitriptyline group (4.8 vs 3.5; MD, 
-1.3; 95% CI, -1.7 to -0.9), when compared to 
placebo. 
Headache duration (hours/month) at 
12 weeks was reduced in both groups (ami-
triptyline MD, -4.4 hours; 95% CI, -5.1 to -3.9; 
melatonin MD, -4.8 hours; 95% CI, -5.7 to 
-3.9), as was the number of analgesics used 
(amitriptyline MD, -1; 95% CI, -1.5 to -0.5; 
melatonin MD, -1; 95% CI, -1.4 to -0.6) when 
compared to placebo. There was no signifi-
cant difference between the melatonin and 
amitriptyline groups for these outcomes. 
Patients taking melatonin were more 
likely to have a >50% improvement in head-
ache frequency compared to amitripty-
line (54% vs 39%; number needed to treat 
[NNT]=7; P<.05); melatonin worked much 
better than placebo (54% vs 20%; NNT=3; 
P<.01). 
Adverse events were reported more 
often in the amitriptyline group than in 
the melatonin group (46 vs 16; P<.03) with 
daytime sleepiness being the most frequent 
complaint (41% of patients in the amitrip-
tyline group vs 18% of the melatonin group; 
number needed to harm [NNH]=5). There 
was no significant difference in adverse 
events between melatonin and placebo 
(16 vs 17; P=not significant). Melatonin 
resulted in weight loss (mean, -0.14 kg), 
whereas those taking amitriptyline gained 
weight (+0.97 kg; P<.01). 
WHAT’S NEW
An effective migraine prevention 
alternative with minimal adverse effects
Melatonin is an accessible and afford-
able option for preventing migraine head-
aches in chronic sufferers. The 3-mg dosing 
reduces headache frequency—both in terms 
of the number of migraine headache days 
per month and in terms of the percentage of 
patients with a >50% reduction in headache 
events—as well as headache intensity, with 
minimal adverse effects. 
CAVEATS
Product consistency, missing study data
This trial used 3-mg dosing, so it is not clear 
if other doses are also effective. In addition, 
because melatonin is available over-the-
counter, the quality/actual doses may be less 
well regulated, and thus, there may be a lack 
of consistency between brands. Unlike clini-
cal practice, neither the amitriptyline nor 
the melatonin dose was titrated according 
to patient response or adverse effects. As a 
result, we are not sure of the actual lowest 
effective dose, or if greater effect (with con-
tinued minimal adverse effects) could be 
achieved with higher doses. 
Lastly, 69% to 75% of patients in the 
treatment groups completed the 16-week 
trial, but the authors of the study reported 
using 3 different analytic techniques to 
estimate missing data. The primary out-
come included 178 of 196 randomized 
patients (90.8%). For the primary endpoint, 
the authors treated all missing data as non-
headache days. It is unclear how these miss-
ing data would affect the outcome, although 
an analysis like this would tend towards a null 
effect. 
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CHALLENGES TO IMPLEMENTATION
Challenges are negligible
There are really no challenges to imple-
menting this practice changer; melatonin is 
readily available over-the-counter and it is 
affordable.                      JFP
ACKNOWLEDGEMENT
The PURLs Surveillance System was supported in part by 
Grant Number UL1RR024999 from the National Center For 
Research Resources, a Clinical Translational Science Award to 
the University of Chicago. The content is solely the responsi-
bility of the authors and does not necessarily represent the 
official views of the National Center For Research Resources 
or the National Institutes of Health.
Copyright © 2017. The Family Physicians Inquiries Network. 
All rights reserved. 
References 
 1.   Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Randomised 
clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and 
placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 
2016;87:1127-1132.
 2.   Silberstein SD, Holland S, Freitag F, et al. Evidence-based guide-
line update: pharmacologic treatment for episodic migraine pre-
vention in adults: report of the Quality Standards Subcommittee 
of the American Academy of Neurology and the American Head-
ache Society. Neurology. 2012;78:1337-1345.
 3.   Lipton RB, Bigal ME, Diamond M, et al; The American Migraine 
Prevalence and Prevention Advisory Group. Migraine preva-
lence, disease burden, and the need for preventive therapy. Neu-
rology. 2007;68:343-349.
 4.   Silberstein SD. Practice parameter: evidence-based guidelines 
for migraine headache (an evidence-based review): report of the 
Quality Standards Subcommittee of the American Academy of 
Neurology. Neurology. 2000;55:754-762.
 5.   Alstadhaug KB, Odeh F, Salvesen R, et al. Prophylaxis of mi-
graine with melatonin: a randomized controlled trial. Neurology. 
2010;75:1527-1532.
This supplement is sponsored by Primary Care Education Consortium and Primary Care Metabolic Group 
and is supported by funding from Janssen Pharmaceuticals, Inc.
To read the supplement, visit the Education 
Center section on The Journal of Family 
Practice website:
A SUPPLEMENT TO THE JOURNAL OF FAMILY PRACTICE 
Elements for Success in 
Managing Type 2 Diabetes 
With SGLT-2 Inhibitors
ONLINE NOW!
Eden M. Miller, DO
Executive Director and Co-founder, Diabetes Nation
High Lakes Health Care
St. Charles Hospital
Bend, Oregon
▼
▼
This supplement highlights the role of the 
kidney and the beneﬁ ts of SGLT-2 inhibitors in 
individualizing treatment for type 2 diabetes.
MDEDGE.COM/JFP/
EDUCATION-CENTER/LATEST
PCEC_SGLT-2 AD 0217.indd   1 2/17/17   10:15 AM
